| Immune Implications of Cholesterol-Containing Lipid Nanoparticles PI Back, M Yu, S Modaresahmadi, S Hajimirzaei, Q Zhang, MR Islam, ... ACS nano 18 (42), 28480-28501, 2024 | 1 | 2024 |
| CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies MH Faeq, M Al-Haideri, TAM Mohammad, F Gharebakhshi, F Marofi, ... Medical Oncology 40 (5), 155, 2023 | 1 | 2023 |
| Distinguishing adverse drug reactions, the noxious effects of medicines at a tertiary care hospital SS Nia, S Modaresahmadi, AE Zaei hospital 8, 69-73, 2018 | 1 | 2018 |
| Multidrug-resistant polymicrobial bacteremia and sepsis: A rare case report SS NIA, S MODARESAHMADI, V THIRUMOORTHI, Q ANWAR, ... Asian J Pharm Clin Res 11 (9), 5-8, 2018 | 1 | 2018 |
| Thirty years from FDA approval of Pegylated Liposomal Doxorubicin (Doxil®/Caelyx™): an updated analysis and future perspective NMLB Alberto A Gabizon, Shira Gabizon- Peretz, Shadan Modaresahmadi BMJ Oncology 4 (1), 2025 | | 2025 |
| 128 Finding optimal targets for complement-based cancer therapy S Modaresahmadi, A Silwal, M Kolev, M Karbowniczek, M Markiewski Immunobiology 228 (5), 152579, 2023 | | 2023 |
| Assessment of Adverse Drug Reactions Associated with Cardiovascular Agents and Antibiotics at a Tertiary Care Hospital AE Zaei, SS Nia, S Modaresahmadi Asian Journal of Pharmaceutical Research and Health Care, 54-59, 2018 | | 2018 |
| Appraising risk of development of cardiovascular disease in patients with type 2 diabetes mellitus S Modaresahmadi, SRR HIREMATH, T Vithya, S Prasad, A Bobbins, ... Heart India 6 (2), 39-44, 2018 | | 2018 |
